Human adipose-derived cells: an update on the transition to clinical translation.
Human adipose-derived cells: an update on the transition to clinical translation.
复制标题
DOI：
10.2217/rme.11.119
复制
发表时间：
2012-03
影响因子：
2.7
通讯作者：
Guilak F
中科院分区：
文献类型：
--
作者：
Gimble JM;Bunnell BA;Guilak F
在临床前和临床转化水平上，涉及脂肪源性细胞的发现步伐继续加快。脂肪组织是新鲜分离的、异质基质血管部分细胞和培养扩增的、粘附的和相对同质的脂肪基质/干细胞的来源。这两个群体在软组织和硬组织修复、缺血性损伤和自身免疫性疾病方面都显示出再生能力。虽然它们的主要作用机制被归因于直接谱系分化和/或旁分泌因子释放，但目前的证据支持旁分泌机制。在15个国家进行的40多项使用脂肪来源细胞的临床试验已在NIH注册，其中大多数是I期或I/II期安全性研究。本文综述了近2年来脂肪源性细胞治疗再生医学的临床和临床前研究进展。
The pace of discovery involving adipose-derived cells continues to accelerate at both the preclinical and clinical translational levels. Adipose tissue is a source of freshly isolated, heterogeneous stromal vascular fraction cells and culture-expanded, adherent and relatively homogeneous adipose stromal/stem cells. Both populations display regenerative capacity in soft and hard tissue repair, ischemic insults and autoimmune diseases. While their major mechanism of action has been attributed to both direct lineage differentiation and/or paracrine factor release, current evidence favors a paracrine mechanism. Over 40 clinical trials using adipose-derived cells conducted in 15 countries have been registered with the NIH, the majority of which are Phase I or Phase I/II safety studies. This review focuses on the literature of the past 2 years in order to assess the status of clinical and preclinical studies on adipose-derived cell therapies for regenerative medicine.